基本信息
views: 16
Career Trajectory
Bio
Dr Link is a CSIC researcher focussed on molecular mechanisms cancer and aging. He is co-founder of Refoxy Pharma GMBH, a biotech company dedicated to develop pharmaceuticals to target FOXO proteins. Dr Link counts with more than 25 years of experience in basic and translational biomedical research, and has been an independent researcher for over 15 years. He holds three patents (one licensed to Sanofi), published three books, three book chapters and over 90 articles (4 more under revision), 10 as first author, over 40 as senior author. He published articles (selection) in Nature, Oncogene, Drug Resistance Updates, PNAS, Nature Communications, Nature Reviews Drug Discovery, Trends in Biotechnology, EMBO J, The Lancet Oncology and Aging Cell. His work has been cited 5914 times. He also serves as an editorial board member of prestigious, international peer reviewed journals including Cancers, Frontiers in Oncology and Frontiers in Cell and Developmental Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019). Dr Link acts as an expert evaluator for funding organisations including ERC (EU), The Brain Tumour Charity (UK), Leuka (UK), Dutch Cancer Society (Netherlands), Austrian Science Fund (ASF, Austria), ANEP (Spain), FCT (Portugal), MOH (Italy), AIFA (Italy), University of Macau (China), HRC (New Zealand). He also serves as a peer-reviewer for (selection) Carcinogenesis, Chemical Reviews, Drug Discovery Today, FEBS Letters, Hepatology, International Journal of Cancer, J Cell Science, Nature Chemical Biology, Nature Comm., Oncogene, PloS ONE, PNAS, Scientific Reports, Trends in Cell Biology. Dr Link built an extensive network of contacts and collaborations (member of three COST actions, majority of published papers from the Link lab include national and international collaborators). He has a proven track-record in drug discovery and drug development and has recently published a textbook on that topic (Link W. Springer Nature 2019).
He obtained his PhD degree in molecular neuroscience from the University of Hamburg, followed by a short postdoc at CNB (Madrid), before joining the pharma/biotech company EleGene AG (Martinsried, Germany) as a senior scientist. In 2001, he moved to Madrid joining the newly-founded CNIO where he was promoted head of drug screening in 2010. In 2011, he accepted a position as assistant professor at the faculty of Biomedical Sciences and Medicine (University of Algarve, Portugal) where he was head of the Department of Oncobiology and director of a Master´s program on Molecular Mechanisms of Cancer. He has supervised 7 Post-doctoral fellows, 4 PhD students, 15 Master students. Dr Link is a leading expert in High Content Screening technology and the biology of FOXO and Tribbles proteins.
Research Interests
Papers共 102 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCERSno. 14 (2023): 3547-3547
CELL DEATH & DISEASEno. 12 (2023)
Cell Death & Diseaseno. 12 (2023): 797-797
Cell death & diseaseno. 10 (2023): 702-16
Ana Luísa De Sousa-Coelho,Manuel Aureliano,Gil Fraqueza, Gisela Serrão, João Gonçalves,Irma Sánchez-Lombardo,Wolfgang Link,Bibiana I Ferreira
Lucia Jimenez,Victor Mayoral-Varo, Carlos Amenábar, Judit Ortega,João G N Sequeira,Miguel Machuqueiro,Cristiana Mourato,Romano Silvestri,Andrea Angeli,Fabrizio Carta,Claudiu T Supuran,Diego Megías,
Load More
Author Statistics
#Papers: 109
#Citation: 6126
H-Index: 32
G-Index: 78
Sociability: 6
Diversity: 1
Activity: 1
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn